The flavonoid quercetin is an aglycone of many plant flavonoid glycosides, including rutin. the pharmacological properties of quertin are due to the pronounced antioxidant activity of the preparation. due to the capillary stabilizing property associated with the antioxidant, membrane stabilizing effect, the preparation reduces capillary permeability. Quercetin has an anti-inflammatory effect, which is due to the blockade of the lipoxygenase pathway of the metabolism of arachidonic acid, a decrease in the synthesis of leukotrienes, serotonin and other inflammatory mediators.
Quvertin has a gastroprotective effect.
The cardioprotective property of Quvertin is due to an increase in the energy supply of cardiomyocytes due to its antioxidant effect and an improvement in blood circulation.
The reparative property of Quertin is accelerated wound healing. The preparation can affect the processes of bone tissue remodeling, exhibits stable immunomodulatory activity.
The diuretic, antispasmodic, antisclerotic properties of the preparation were also experimentally determined. Quvertin is able to normalize blood pressure and stimulate the release of insulin, inhibit thromboxane synthesis, and slow down platelet aggregation.
Quertin also binds to estrogen receptors. Due to estrogen-like properties (effect on proline hydroxylase, inhibition of tumor necrosis factor and synthesis of interleukins), the preparation has a proosteoclastic effect.
As part of a comprehensive treatment:
The preparation is taken orally 30 minutes before meals. the tablets are chewed with a little water.
In the complex treatment of neuroreflex manifestations of osteochondrosis of the spine, chronic glomerulonephritis, ischemic heart disease, as well as to prevent the ulcerogenic action of NSAIDs, Quvertin is prescribed for adults 1 tablet 3 times a day. In the complex treatment of purulent-inflammatory diseases of soft tissues, 1 tablet is prescribed 2 times a day. With simultaneous use with NSAIDs in adults, it is possible to use Quvertin 2 tablets 3 times a day.
With neurocirculatory dystonia, the preparation is prescribed 2 tablets 2 times a day for 1 month.
In the complex treatment of climacteric and vertebral pain syndrome, Quvertin is prescribed 1 tablet 3 times a day. The treatment period is 6 months.
Hypersensitivity to quercetin and other components of the preparation, as well as to preparations with p-vitamin activity.
Headache, tingling sensation in the extremities, nausea, hypersensitivity reactions, including rash, itching may occur.
Since the preparation contains sucrose and glucose, patients with hereditary intolerance to fructose, glucose-galactose, sucrose-isomaltose should not take the preparation.
Quvertin, chewable tablets, should be used with caution in patients with removable dentures.
The preparation should be used with caution in patients with diabetes mellitus.
Use during pregnancy and lactation. It is not recommended to use the preparation during pregnancy and lactation.
If the preparation is prescribed to women who are breastfeeding, breastfeeding should be discontinued for the period of treatment.
Children. There is no experience of using Quvertin in children under the age of 12, therefore it is not recommended to use the preparation in patients of this age group.
The ability to influence the reaction rate when driving or operating machinery. Does not affect.
When using quercetin with:
Information about an overdose of Quertin has not been reported. an increase in the severity of manifestations of adverse reactions is possible.
Treatment is symptomatic.
In its original packaging at a temperature not exceeding 25 ° C.
There are no reviews for this product.